FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2586076618> ?p ?o ?g. }

• W2586076618 abstract "Abstract Abstract 890 Background: One of the most extensively used approaches to prevent GVHD in the RIC setting is the combination of CsAMMF. Other strategies have been described such as SiTac, mostly as single center experiences, with promising results. Nevertheless, data from multicenter studies are lacking using the latter approach and, furthermore, no studies have been performed comparing both approaches. Aim: in the current study we describe the results of the prospective multicenter trial 2007–006416-32 by GEL-TAMO/GETH using SiTac as GVHD prophylaxis and compare this approach to the combination of CsAMMF in a sequential analysis. Material and Methods: from May 2002, 90 patients were included. All of them received an URD transplantation after RIC based on fludarabine (150 mg/m2) plus busulphan (10 mg/kg) or melphalan (140 mg/m2). 45 transplanted between 2002 a 2007 received CsAMMF as GVHD prophylaxis while the remaining 45 patients undergoing transplantation from 2008 received SiTac. 41% of the patients were in CR, 30% were in PR and 29% had active disease at the time of transplantation. No differences were observed in terms of disease status. Patients in the SiTac trial had a higher median age (49 versus 43 years, p=0.02) while a higher percentage of patients in the CsAMMF were diagnosed with acute leukemia (10 versus 19 patients, p=0.05). Supportive care was similar in both subgroups except for the use of azols as antifungal prophylaxis which was not allowed in the SiTac. Results: 12% of patients receiving SiTac developed mycroangiopathy which required to modify immunesuppresive treatment although it did not increase the mortality of the procedure. No VOD was reported. No significant differences were observed neither in terms of hematopoietic recovery nor in the cumulative incidence of grades 2–4 or 3–4 aGVHD (49% versus 50% grades 2–4 and 15% versus 26% grades 3–4 for patients receiving SiTac versus CsAMMF, respectively). By contrast 18% of patients receiving SiTac versus 55% of those receiving CsAMMF developed gut aGVHD ≥ grade 2, p=0.007. Cumulative incidence of cGVHD was 55% versus 88% for SiTac versus CsAMMF, respectively, p=0.0002 while the incidence of extensive cGVHD was 27% versus 52%, respectively, p=0.03. Non relapse mortality was 10% versus 20% at 100 days and 19% versus 40% at 1 year, for patients receiving Si-Tac versus CsAMMF, respectively (p=0.028). Event free and overall survival at 2 years were 59% versus 35%, p=0.008 and 72 versus 48%, p=0.018, for patients receiving Si-Tac versus CsAMMF, respectively. Conclusions: the current study confirms in a multicenter trial the promising results of the combination Sirolimus plus Tacrolimus among patients undergoing RIC URD transplantation. The current is the first study comparing in a sequential study SiTac versus CsAMMF and confirms that the prior decreases the risk of chronic GVHD and the non-relapse mortality of the procedure which translates into a better event free and overall survival. Disclosures: No relevant conflicts of interest to declare." @default.
• W2586076618 created "2017-02-17" @default.
• W2586076618 creator A5008285347 @default.
• W2586076618 creator A5008597414 @default.
• W2586076618 creator A5020211212 @default.
• W2586076618 creator A5022714308 @default.
• W2586076618 creator A5043541529 @default.
• W2586076618 creator A5053474378 @default.
• W2586076618 creator A5054374372 @default.
• W2586076618 creator A5061223719 @default.
• W2586076618 creator A5075722788 @default.
• W2586076618 creator A5084819549 @default.
• W2586076618 creator A5089418637 @default.
• W2586076618 creator A5090462017 @default.
• W2586076618 date "2011-11-18" @default.
• W2586076618 modified "2023-10-09" @default.
• W2586076618 title "The Combination of Siromilus Plus Tacrolimus (SiTac) Improves the Results of Cyclosporine Plus Mycophenolate Mofetil (CsAMMF) After Reduced Intensity Conditioning (RIC) Unrelated Donor Allogeneic Transplantation" @default.
• W2586076618 doi "https://doi.org/10.1182/blood.v118.21.890.890" @default.
• W2586076618 hasPublicationYear "2011" @default.
• W2586076618 type Work @default.
• W2586076618 sameAs 2586076618 @default.
• W2586076618 citedByCount "0" @default.
• W2586076618 crossrefType "journal-article" @default.
• W2586076618 hasAuthorship W2586076618A5008285347 @default.
• W2586076618 hasAuthorship W2586076618A5008597414 @default.
• W2586076618 hasAuthorship W2586076618A5020211212 @default.
• W2586076618 hasAuthorship W2586076618A5022714308 @default.
• W2586076618 hasAuthorship W2586076618A5043541529 @default.
• W2586076618 hasAuthorship W2586076618A5053474378 @default.
• W2586076618 hasAuthorship W2586076618A5054374372 @default.
• W2586076618 hasAuthorship W2586076618A5061223719 @default.
• W2586076618 hasAuthorship W2586076618A5075722788 @default.
• W2586076618 hasAuthorship W2586076618A5084819549 @default.
• W2586076618 hasAuthorship W2586076618A5089418637 @default.
• W2586076618 hasAuthorship W2586076618A5090462017 @default.
• W2586076618 hasConcept C126322002 @default.
• W2586076618 hasConcept C141071460 @default.
• W2586076618 hasConcept C2776694085 @default.
• W2586076618 hasConcept C2776755627 @default.
• W2586076618 hasConcept C2778684742 @default.
• W2586076618 hasConcept C2779263901 @default.
• W2586076618 hasConcept C2909675724 @default.
• W2586076618 hasConcept C2911091166 @default.
• W2586076618 hasConcept C71924100 @default.
• W2586076618 hasConcept C90924648 @default.
• W2586076618 hasConceptScore W2586076618C126322002 @default.
• W2586076618 hasConceptScore W2586076618C141071460 @default.
• W2586076618 hasConceptScore W2586076618C2776694085 @default.
• W2586076618 hasConceptScore W2586076618C2776755627 @default.
• W2586076618 hasConceptScore W2586076618C2778684742 @default.
• W2586076618 hasConceptScore W2586076618C2779263901 @default.
• W2586076618 hasConceptScore W2586076618C2909675724 @default.
• W2586076618 hasConceptScore W2586076618C2911091166 @default.
• W2586076618 hasConceptScore W2586076618C71924100 @default.
• W2586076618 hasConceptScore W2586076618C90924648 @default.
• W2586076618 hasLocation W25860766181 @default.
• W2586076618 hasOpenAccess W2586076618 @default.
• W2586076618 hasPrimaryLocation W25860766181 @default.
• W2586076618 hasRelatedWork W2122587491 @default.
• W2586076618 hasRelatedWork W2344289333 @default.
• W2586076618 hasRelatedWork W2400726922 @default.
• W2586076618 hasRelatedWork W2407946965 @default.
• W2586076618 hasRelatedWork W2417243587 @default.
• W2586076618 hasRelatedWork W2532749935 @default.
• W2586076618 hasRelatedWork W2553641084 @default.
• W2586076618 hasRelatedWork W2555693113 @default.
• W2586076618 hasRelatedWork W2559985421 @default.
• W2586076618 hasRelatedWork W2560608436 @default.
• W2586076618 hasRelatedWork W2563868984 @default.
• W2586076618 hasRelatedWork W2565864774 @default.
• W2586076618 hasRelatedWork W2589631483 @default.
• W2586076618 hasRelatedWork W2592606920 @default.
• W2586076618 hasRelatedWork W2594121809 @default.
• W2586076618 hasRelatedWork W2793141239 @default.
• W2586076618 hasRelatedWork W2980021387 @default.
• W2586076618 hasRelatedWork W3001261600 @default.
• W2586076618 hasRelatedWork W3095901934 @default.
• W2586076618 hasRelatedWork W3124594380 @default.
• W2586076618 isParatext "false" @default.
• W2586076618 isRetracted "false" @default.
• W2586076618 magId "2586076618" @default.
• W2586076618 workType "article" @default.